Unveiling the TrkA-p35/CDK5 axis: a novel therapeutic target in diabetic kidney disease

Area of Science:

• Nephrology
• Molecular Biology
• Pharmacology

Background:

• Diabetic kidney disease (DKD) is a major complication of diabetes, characterized by podocyte injury and inflammation.
• The role of neurotrophic signaling pathways, such as TrkA (high-affinity nerve growth factor receptor), in DKD pathogenesis is not fully understood.
• Potential crosstalk between TrkA and cyclin-dependent kinase 5 (CDK5) in DKD requires investigation.

Purpose of the Study:

• To investigate the crosstalk between TrkA and CDK5 in the pathogenesis of diabetic kidney disease (DKD).
• To evaluate the therapeutic potential of targeting TrkA in DKD.
• To elucidate the molecular mechanisms linking TrkA activation to podocyte injury in DKD.

Main Methods:

• Renal transcriptional profiles were analyzed in db/db mice (DKD model) and controls using RNA sequencing.
• An in vitro model of podocyte injury was induced by high glucose (HG) stimulation.
• The efficacy of a TrkA inhibitor (GW441756) was assessed in both DKD model mice and HG-stimulated podocytes.

Main Results:

• NGFR (TrkA receptor) was upregulated in db/db mice kidneys.
• High glucose increased TrkA phosphorylation at Tyr490 in podocytes, aggravating injury.
• TrkA activation was mechanistically linked to CDK5, leading to p35/CDK5 activation, downstream ERK/EGR1 signaling, and inflammation-mediated podocyte injury.
• TrkA inhibition reduced TrkA phosphorylation and attenuated inflammation.

Conclusions:

• A TrkA-p35/CDK5 signaling axis contributes to podocyte inflammation and injury in DKD.
• This pathway connects neurotrophic signaling with renal metabolic inflammation via a novel mechanism.
• TrkA inhibition demonstrates therapeutic potential for DKD by mitigating podocyte inflammation and injury.